EGI
VTGN icon

EAM Global Investors’s VistaGen Therapeutics VTGN Stock Holding History

EAM Global Investors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21,158
Closed -$1.74M – 271
2021
Q3 		$1.74M Buy
+21,158
New +$1.84M 0.41% 112

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

EAM Global Investors's VTGN Position: Q4 2021 in Review

EAM Global Investors sold out of VistaGen Therapeutics (VTGN) in Q4 2021, closing a stake of 21,158 shares — an estimated $1.74M sold.

EAM Global Investors first reported a position in VTGN in Q3 2021 and held it in 1 quarter. The position peaked at $1.74M in Q3 2021. 106 funds tracked by Wall St. Rank hold VTGN as of Q4 2021.

  • EAM Global Investors reported no remaining VistaGen Therapeutics position as of Q4 2021 after selling out during the quarter.
  • EAM Global Investors sold 21,158 VistaGen Therapeutics shares in Q4 2021, an estimated $1.74M.
  • EAM Global Investors first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 1 quarter.
  • EAM Global Investors's VistaGen Therapeutics position peaked at $1.74M in Q3 2021.
  • 106 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2021.

Based on EAM Global Investors's 13F filing for Q4 2021, filed 11 Feb 2022.